Quarterly Results Presentation

First Quarter of 2017

May 1, 2017

FORWARD-LOOKING STATEMENTS

Certain statements in this presentation constitute “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include, but are not limited to, the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2016 and other filings with the Securities and Exchange Commission.

NON-GAAP FINANCIAL INFORMATION

This presentation contains non-GAAP financial measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measure are included in the financial tables at the end of this presentation as well as at the end of the Company’s press release dated May 1, 2017.

Summary of Key Announcements

Humana agreement

- All of Tenet's hospitals, hospital-affiliated outpatient centers and employed physicians will be phased back into Humana's network between June 1st and October 1st.
- All of USPIs facilities will be added to Humana's network on June 1st.
- The new contract runs through May 2020.

Agreement to increase ownership of USPI to 80% on or before July 3, 2017

- See slide 5 for additional details.

Selling three acute care hospitals in Houston for approximately $725 million

- Transaction expected to be completed in Q3'17.
- Anticipate net cash proceeds of approximately $725 million.
- Net revenue after the provision for doubtful accounts was approximately $575 million in 2016.
- EBITDA was approximately $80 million in 2016, representing a margin of approximately 14%.
- Tax basis is approximately $250 million. Approximately $500 million of the Company's $1.7 billion NOL will be used to offset taxable gains on this sale.

Health plan, home health and hospice divestitures

- $65 million of total proceeds anticipated from multiple transactions, including $6 million that was received in Q4'16.
- $14 million received in Q1'17 from the sale of Harbor Health Plan in Michigan.
- Approximately $45 million anticipated in Q2'17 from the sale of certain home health and hospice businesses on May 1, the sale of Phoenix Health Plan on May 1, and the expected sale of Allegian Health Plans in Texas during Q2'17.

Q1’17 Financial Highlights

- **Adjusted EBITDA was $527 million**
  - Adjusted EBITDA included a previously unanticipated $7 million benefit from a change in pension accounting rules.
  - The $90 million decline in Adjusted EBITDA as compared to $617 million in Q1’16 was primarily due to:
    - $57 million of revenue being recorded under the California Provider Fee program in Q1’16 versus no revenue being recorded related to this program in Q1’17.
    - $25 million of EBITDA in Q1’16 generated by Tenet’s hospitals in Atlanta, Georgia, which were divested on April 1, 2016.
    - $7 million of start-up losses in Q1’17 at the Company’s new hospital in El Paso, Texas which opened in January 2017.
  - As noted in the Company’s Q4’16 earnings release, the results of the Company’s health plans are being excluded from Adjusted EBITDA in both 2017 and prior periods. In Q1’17, the health plan business generated losses of $16 million as compared to positive EBITDA of $3 million in Q1’16. In addition, the change in accounting for pension expense raised Adjusted EBITDA by $7 million in both Q1’16 and Q1’17. These changes resulted in a historical restatement of the Company’s Q1’16 EBITDA to $617 million as compared to the $613 million that was originally reported for Q1’16.
- **Hospital segment same-hospital patient revenue declined 1.0%**
  - Adjusted admissions decreased 2.5% on a same-hospital basis and were down 0.8% excluding patients insured by Humana in both periods.
  - Admissions decreased 3.3% on a same-hospital basis and were down 1.7% excluding patients insured by Humana in both periods.
  - Revenue per adjusted admission increased 1.6% and was up 3.0% after adjusting for the California Provider Fee.
  - Hospital segment Adjusted EBITDA was $309 million and was down $109 million compared to $418 million in Q1’16, primarily driven by the California Provider Fee, divestitures in Atlanta and start-up losses in El Paso, as listed above. A $34 million increase in same-hospital bad debt also contributed to this decline.
- **Ambulatory Care same-facility system-wide revenue grew 6.1%**
  - Cases increased 0.5% and revenue per case increased 5.6% on a same-facility system-wide basis. Cases grew 2.4% excluding Humana in both periods.
  - Ambulatory Care Adjusted EBITDA was $153 million, up 12.5% from $136 million in Q1’16.
  - Ambulatory Care Adjusted EBITDA less facility-level NCI was $100 million, up 11.1% from $90 million in Q1’16.
- **Conifer’s revenue increased 4.4% to $402 million driven by an 11.5% increase in third party revenue**
  - Adjusted EBITDA increased 3.2% to $65 million, representing a margin of 16.2%.

Accelerating the Purchase of United Surgical Partners International

Summary of Key Terms

- Increasing Tenet's ownership in USPI to 80% on or before July 3.
- Anticipate increasing Tenet's ownership interest in USPI to 87.5% in July 2018 and 95% in July 2019; a subsidiary of Baylor Scott & White Health will own the remaining 5%.
- Tenet to pay Welsh Carson $711 million on or before July 3, 2017, funded through available liquidity.
- Projected payments are expected to be in the range of $275 million to $325 million each year in both 2018 and 2019, based on an enterprise value multiple of 10x EBITDA less facility level NCI. The Company plans to fund these payments through free cash flow generation.

Advantages

- Reduces complexity and lowers the amount of future capital that is pre-committed to completing the buy-up of USPI.
- More of the value of USPI's growth accrues to the benefit of Tenet's shareholders faster.
- Positive net present value.
- With 80% ownership, Tenet can include USPI in its consolidated tax return and use Tenet's NOL to offset USPI's taxable income.
- Reduces redeemable NCI on the balance sheet by approximately $700 million on or before July 3, 2017.
- Continue to target a debt-to-EBITDA ratio of approximately 5x by the end of 2019.

Today



July 2017
$711 million



July 2018
$275-$325 million



July 2019
$275-$325 million



Revenue and EBITDA by Segment

$ in millions	Q1'15	Q2'15	Q3'15	Q4'15	2015	Q1'16	Q2'16	Q3'16	Q4'16	2016	Q1'17
Hospital Operations and Other											
Net operating revenues after bad debt [1]	$4,246	$4,175	$4,179	$4,423	$17,023	$4,397	$4,202	$4,162	$4,143	$16,904	$4,050
EBITDA	$447	$459	$383	$394	$1,683	$414	$415	$334	$358	$1,521	$309
EBITDA margin	*10.5%*	*11.0%*	*9.2%*	*8.9%*	*9.9%*	*9.4%*	*9.9%*	*8.0%*	*8.6%*	*9.0%*	*7.6%*
Ambulatory Care											
Net operating revenues after bad debt	n/a	$142	$329	$397	$868	$429	$442	$448	$478	$1,797	$455
EBITDA	n/a	$49	$122	$158	$329	$136	$139	$157	$183	$615	$153
EBITDA margin	n/a	*34.5%*	*37.1%*	*39.8%*	*37.9%*	*31.7%*	*31.4%*	*35.0%*	*38.3%*	*34.2%*	*33.6%*
Conifer											
Net operating revenues after bad debt	$342	$340	$347	$384	$1,413	$385	$386	$398	$402	$1,571	$402
EBITDA	$82	$60	$61	$61	$264	$63	$63	$79	$72	$277	$65
EBITDA margin	*24.0%*	*17.6%*	*17.7%*	*15.9%*	*18.7%*	*16.4%*	*16.3%*	*19.8%*	*17.9%*	*17.6%*	*16.2%*
Less: Intercompany eliminations from revenue	-$160	-$165	-$163	-$178	-$666	-$167	-$162	-$159	-$163	-$651	-$159
Total, as reported in each period [2]											
Net operating revenues after bad debt	$4,428	$4,492	$4,692	$5,026	$18,638	$5,044	$4,868	$4,849	$4,860	$19,621	$4,748
EBITDA	$529	$568	$566	$613	$2,276	$613	$617	$570	$613	$2,413	$527
EBITDA margin	*11.9%*	*12.6%*	*12.1%*	*12.2%*	*12.2%*	*12.2%*	*12.7%*	*11.8%*	*12.6%*	*12.3%*	*11.1%*

(1) Hospital Operations and Other revenue excludes $65 million of health plan revenue in Q1'17.

(2) Data is presented on an as reported basis. Historical financial information has not been restated for health plans or changes in pension expense accounting.

Health Plan Financial Results

Health plans are included in the Hospital Operations and Other segment

$ in millions	**Q1'15**	**Q2'15**	**Q3'15**	**Q4'15**	**Q1'16**	**Q2'16**	**Q3'16**	**Q4'16**	**Q1'17**
Net Operating Revenues	**$108**	**$104**	**$106**	**$105**	**$127**	**$136**	**$122**	**$97**	**$65**
Equity in earnings of unconsolidated affiliates	$0	$0	$0	$0	$0	$0	$0	$0	$0
Salaries and Benefits	-$3	-$3	-$4	-$5	-$6	-$6	-$5	-$6	-$5
% of revenue	*2.8%*	*2.9%*	*3.8%*	*4.8%*	*4.7%*	*4.4%*	*4.1%*	*6.2%*	*7.7%*
Supplies	$0	$0	$0	$0	$0	$0	$0	$0	$0
% of revenue	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Other Operating Expenses	-$102	-$90	-$99	-$100	-$118	-$135	-$123	-$120	-$76
% of revenue	*94.4%*	*86.5%*	*93.4%*	*95.2%*	*92.9%*	*99.3%*	*100.8%*	*123.7%*	*116.9%*
Electronic Health Record Incentives	$0	$0	$0	$0	$0	$0	$0	$0	$0
EBITDA	**$3**	**$11**	**$3**	**$0**	**$3**	**-$5**	**-$6**	**-$29**	**-$16**
EBITDA margin	***2.8%***	***10.6%***	***2.8%***	***0.0%***	***2.4%***	***-3.7%***	***-4.9%***	***-29.9%***	***-24.6%***

Same Hospital Growth Rates

	Q1'15	Q2'15	Q3'15	Q4'15	2015	Q1'16	Q2'16	Q3'16	Q4'16	2016	Q1'17
Adjusted Admissions	4.7%	-3.4%	0.7%	0.3%	**2.4%**	2.2%	0.5%	1.4%	-0.5%	**0.9%**	-2.5%
Admissions	2.0%	0.1%	-0.6%	-1.8%	**1.1%**	-0.1%	-1.1%	0.4%	-0.2%	**-0.2%**	-3.3%
Revenue Per Adjusted Admission	4.7%	2.4%	5.8%	0.3%	**3.1%**	3.7%	3.9%	3.9%	3.7%	**3.8%**	1.6%
Inpatient Surgeries	5.7%	-3.1%	-0.2%	-0.9%	**0.8%**	0.2%	-0.1%	0.2%	-2.0%	**-0.4%**	-3.8%
Outpatient Surgeries	8.1%	-5.7%	1.5%	0.6%	**1.3%**	5.6%	2.0%	-3.6%	-1.5%	**0.5%**	-6.5%
Emergency Department Visits	6.1%	-4.1%	1.5%	-0.6%	**2.7%**	4.8%	0.9%	0.5%	-0.7%	**1.3%**	-4.0%
Total Outpatient Visits	7.2%	-5.5%	3.0%	3.0%	**4.5%**	5.2%	0.8%	0.8%	-1.3%	**1.4%**	-2.1%

Same Hospital Revenue Growth

Same hospital revenue per adjusted admission growth with and without California Provider Fee revenue

$ in millions, except per adjusted admission	Q1'15	Q2'15	Q3'15	Q4'15	2015	Q1'16	Q2'16	Q3'16	Q4'16	2016	Q1'17
Current Period same-hospital metrics											
Inpatient revenue	$2,648	$2,576	$2,472	$2,546	$10,079	$2,616	$2,400	$2,435	$2,442	$9,776	$2,605
Outpatient revenue	$1,469	$1,438	$1,427	$1,446	$5,630	$1,400	$1,343	$1,333	$1,340	$5,347	$1,463
Total patient revenue	$4,117	$4,014	$3,899	$3,992	$15,709	$4,016	$3,743	$3,768	$3,782	$15,123	$4,068
Patient revenue growth	**8.7%**	**6.9%**	**6.5%**	**0.7%**	**5.5%**	**6.0%**	**4.4%**	**5.3%**	**3.2%**	**4.8%**	**-1.0%**
Adjusted admissions	343,658	340,791	332,498	332,037	1,333,227	330,575	309,372	310,253	303,912	1,239,324	339,522
Adjusted admissions growth	**5.9%**	**2.3%**	**0.7%**	**0.3%**	**2.4%**	**2.2%**	**0.5%**	**1.4%**	**-0.5%**	**0.9%**	**-2.5%**
Revenue per adjusted admission	$11,980	$11,778	$11,726	$12,023	$11,783	$12,149	$12,099	$12,145	$12,444	$12,203	$11,982
Revenue per adjusted admissions growth	**2.7%**	**4.5%**	**5.8%**	**0.3%**	**3.1%**	**3.7%**	**3.9%**	**3.9%**	**3.7%**	**3.8%**	**1.6%**
California Provider Fee	$43	$48	$48	$49	$188	$57	$55	$55	$65	$232	$0
Total patient revenue excluding California Provider Fee	$4,074	$3,966	$3,851	$3,943	$15,521	$3,959	$3,688	$3,713	$3,717	$14,891	$4,068
Patient revenue growth excluding CA Provider Fee	**7.6%**	**5.6%**	**5.2%**	**3.7%**	**5.4%**	**5.7%**	**4.2%**	**5.2%**	**2.8%**	**4.5%**	**0.4%**
Revenue per adjusted admission excl. CA Provider Fee	$11,855	$11,638	$11,582	$11,875	$11,642	$11,976	$11,921	$11,968	$12,231	$12,015	$11,982
Revenue per Adjusted Admission excl. CA Provider Fee	**1.6%**	**3.2%**	**4.5%**	**3.4%**	**3.0%**	**3.4%**	**3.8%**	**3.7%**	**3.3%**	**3.6%**	**3.0%**
Prior Period same-hospital metrics											
Inpatient revenue	$2,440	$2,400	$2,337	$2,591	$9,615	$2,501	$2,305	$2,289	$2,358	$9,334	$2,663
Outpatient revenue	$1,346	$1,355	$1,323	$1,375	$5,271	$1,289	$1,281	$1,288	$1,308	$5,103	$1,445
Total patient revenue	$3,786	$3,755	$3,660	$3,966	$14,886	$3,790	$3,586	$3,577	$3,666	$14,437	$4,108
Adjusted Admissions	324,475	333,073	330,219	330,884	1,301,936	323,577	307,958	305,916	305,436	1,228,039	348,221
Revenue per adjusted admission	$11,668	$11,274	$11,084	$11,986	$11,434	$11,713	$11,644	$11,693	$12,003	$11,756	$11,797
California Provider Fee	$0	$0	$0	$165	$165	$43	$48	$48	$49	$188	$57
Total patient revenue excluding California Provider Fee	$3,786	$3,755	$3,660	$3,801	$14,721	$3,747	$3,538	$3,529	$3,617	$14,249	$4,051
Revenue per adjusted admission excl. CA Provider Fee	$11,668	$11,274	$11,084	$11,487	$11,307	$11,580	$11,489	$11,536	$11,842	$11,603	$11,633

Uncompensated Care Trends

$ in millions	Q1 '15	Q2 '15	Q3 '15	Q4 '15	2015	Q1 '16	Q2 '16	Q3 '16	Q4 '16	2016	Q1 '17
Net Revenue before bad debt	$4,787	$4,843	$5,064	$5,417	**$20,111**	$5,420	$5,220	$5,216	$5,214	**$21,070**	$5,196
Bad Debt Expense	$363	$352	$371	$391	**$1,477**	$376	$352	$367	$354	**$1,449**	$383
% of revenue before bad debt	*7.6%*	*7.3%*	*7.3%*	*7.2%*	***7.3%***	*6.9%*	*6.7%*	*7.0%*	*6.8%*	***6.9%***	*7.4%*
% of adjusted revenue (1)	*6.4%*	*6.2%*	*6.2%*	*6.1%*	***6.2%***	*5.9%*	*5.8%*	*6.0%*	*5.7%*	***5.8%***	*6.2%*
Charity Care Write-Offs	$174	$199	$268	$255	**$896**	$220	$152	$228	$212	**$812**	$181
% of adjusted revenue (1)	*3.1%*	*3.5%*	*4.5%*	*4.0%*	***3.8%***	*3.5%*	*2.5%*	*3.7%*	*3.4%*	***3.3%***	*2.9%*
Uninsured Discounts	$699	$675	$664	$774	**$2,812**	$713	$706	$723	$766	**$2,908**	$778
% of adjusted revenue (1)	*12.3%*	*11.8%*	*11.1%*	*12.0%*	***11.8%***	*11.2%*	*11.6%*	*11.7%*	*12.4%*	***11.7%***	*12.6%*
Uncompensated Care (2)	**$1,236**	**$1,226**	**$1,303**	**$1,420**	**$5,185**	**$1,309**	**$1,210**	**$1,318**	**$1,332**	**$5,169**	**$1,342**
Uncompensated Care Percentage (3)	**21.8%**	**21.4%**	**21.7%**	**22.0%**	**21.8%**	**20.6%**	**19.9%**	**21.4%**	**21.5%**	**20.9%**	**21.8%**

(1) Adjusted Revenue equals the sum of: a) Net operating revenues before provision for doubtful accounts, b) Charity Care Write-Offs, and c) Uninsured Discounts.

(2) Uncompensated Care equals the sum of: a) Bad debt, b) Charity Care Write-Offs, and c) Uninsured Discounts.

(3) The Uncompensated Care Percentage equals: a) Uncompensated Care, divided by b) Adjusted Revenue.

Ambulatory Care Same-Facility System-Wide Growth

Same-facility system-wide growth [1]	USPI only Q1 '15 [2]	<----- Pro forma [3] Q2 '15	Q3 '15	Q4 '15	Q1 '16	Q2 '16	Q3 '16	Q4 '16	2016	-----> Q1 '17
Surgical (ASCs, Surgical Hospitals & Aspen)										
Revenue	8.8%	6.7%	9.9%	12.5%	11.0%	11.8%	9.9%	6.0%	**9.7%**	6.2%
Cases	4.7%	4.8%	5.3%	6.3%	9.0%	5.1%	4.1%	1.5%	**5.0%**	0.5%
Revenue per case	3.9%	1.8%	4.3%	5.9%	1.9%	6.3%	5.5%	4.5%	**4.5%**	5.7%
Non-Surgical (Imaging & Urgent Care)										
Revenue	-	12.4%	15.5%	11.5%	10.9%	9.7%	4.2%	2.9%	**7.3%**	5.1%
Visits	-	13.9%	9.5%	9.3%	8.1%	5.4%	3.7%	2.2%	**5.4%**	0.6%
Revenue per visit	-	-1.3%	5.5%	2.0%	2.6%	4.2%	0.5%	0.7%	**1.8%**	4.5%
Ambulatory Segment Total										
Revenue	-	6.9%	10.1%	12.5%	11.0%	11.7%	9.7%	5.9%	**9.6%**	6.1%
Cases	-	6.8%	6.3%	6.9%	8.6%	5.2%	4.0%	1.7%	**5.2%**	0.5%
Revenue per case	-	0.1%	3.5%	5.2%	2.2%	6.1%	5.5%	4.1%	**4.2%**	5.6%

(1) Same-facility system-wide includes the results of both consolidated and unconsolidated facilities.

(2) The growth rates presented for Q1'15 are based on the same-facility system-wide growth rates reported by USPI-only and exclude: a) the results of Aspen, b) CareSpot, and c) the surgery and imaging centers that Tenet contributed to the USPI joint venture.

(3) The pro forma growth rates for the Ambulatory Segment shown from Q2'15 to Q1'17 include: a) USPI facilities, including its ambulatory surgery centers and surgical hospitals, b) Aspen, c) the surgery and imaging centers that Tenet contributed to the USPI joint venture, and d) CareSpot on a same-facility system-wide basis. Note that CareSpot was acquired by USPI on 12/31/2015 and is included in the growth rates starting in Q1'16.

Ambulatory Care Segment Financials

$ in millions	Q1'15	Q2'15	Q3'15	Q4'15	2015	Q1'16	Q2'16	Q3'16	Q4'16	2016	Q1'17
Net operating revenues	$295	$322	$329	$397	$1,343	$429	$442	$448	$478	$1,797	$455
% growth	*13.9%*	*12.6%*	*14.6%*	*28.9%*	*17.8%*	*45.4%*	*37.3%*	*36.2%*	*20.4%*	*33.8%*	*6.1%*
Equity in earnings of unconsolidated affiliates	$21	$28	$30	$47	$126	$25	$26	$28	$43	$122	$27
Adjusted EBITDA	**$94**	**$115**	**$122**	**$158**	**$489**	**$136**	**$139**	**$157**	**$183**	**$615**	**$153**
% growth	***19.0%***	***4.5%***	***17.3%***	***17.9%***	***14.5%***	***44.7%***	***20.9%***	***28.7%***	***15.8%***	***25.8%***	***12.5%***
Net income attributable to noncontrolling interests (1)	$27	$31	$37	$48	$143	$46	$52	$54	$68	$220	$53
Adjusted EBITDA less NCI (prior to Welsh Carson related NCI) (2)	**$67**	**$84**	**$85**	**$110**	**$346**	**$90**	**$87**	**$103**	**$115**	**$395**	**$100**
% growth	***13.6%***	***2.4%***	***18.1%***	***8.9%***	***10.2%***	***34.3%***	***3.6%***	***21.2%***	***4.5%***	***14.2%***	***11.1%***
Net income attributable to Welsh Carson's ownership interest (2)(3)(4)(5)(6)	$7	$11	$11	$17	$46	$11	$8	$14	$18	$51	$13
Adjusted EBITDA less NCI (after Welsh Carson related NCI) (2)	**$60**	**$73**	**$74**	**$93**	**$300**	**$79**	**$79**	**$89**	**$97**	**$344**	**$87**
% growth	***9.1%***	***2.8%***	***12.1%***	***9.4%***	***8.3%***	***31.7%***	***8.2%***	***20.3%***	***4.3%***	***14.7%***	***10.1%***
Adjusted EBITDA margin	*31.9%*	*35.7%*	*37.1%*	*39.8%*	*36.4%*	*31.7%*	*31.4%*	*35.0%*	*38.3%*	*34.2%*	*33.6%*
Adjusted EBITDA less NCI Margin (prior to Welsh Carson related NCI)	*22.7%*	*26.1%*	*25.8%*	*27.7%*	*25.8%*	*21.0%*	*19.7%*	*23.0%*	*24.1%*	*22.0%*	*22.0%*

Note: These figures represent the pro forma financial results for Tenet's Ambulatory Care segment, including the results for USPI, Aspen and the surgery and imaging centers contributed by Tenet to the USPI joint venture for all periods shown.

(1) Represents subsidiary level NCI expense prior to Tenet recording additional NCI expense related to Welsh Carson's and other USPI shareholders' ownership interest in the USPI joint venture.

(2) The amount labeled as Welsh Carson related NCI represents noncontrolling interest expense related to Welsh Carson's and other USPI shareholders' ownership interest in the USPI joint venture; neither Tenet nor USPI intend to make cash distributions to Welsh Carson or other USPI shareholders.

(3) Welsh Carson related NCI expense was $37 million in Q4'15, but would have been $17 million excluding gains not included in Adjusted EBITDA.

(4) Welsh Carson related NCI expense was $29 million in Q1'16, but would have been $11 million excluding gains not included in Adjusted EBITDA.

(5) Welsh Carson related NCI expense was $15 million in Q3'16, but would have been $14 million excluding gains not included in Adjusted EBITDA.

(6) Welsh Carson related NCI expense was $13 million in Q4'16, but would have been $18 million excluding charges not included in Adjusted EBITDA. During 2016, Welsh Carson related NCI expense was $65 million, but would have been $51 million excluding gains and charges not included in Adjusted EBITDA.

Conifer Health Solutions Segment

Revenue grew 4.4% to $402 million, driven by 11.5% growth in revenue from non-Tenet customers

- Adjusted EBITDA grew 3.2% year-over-year to $65 million in Q1’17.
- Third party revenue growth at Conifer includes business retained from hospitals that Tenet has sold.
- The decline in revenue from Tenet’s hospitals is due to divestitures.

$ in millions	Q1'15 (1)	Q2'15	Q3'15	Q4'15	2015	Q1'16	Q2'16	Q3'16	Q4'16	2016	Q1'17
Revenue from Tenet	$160	$165	$163	$178	$666	$167	$162	$159	$163	$651	$159
% growth	*14.3%*	*19.6%*	*10.1%*	*7.9%*	*12.7%*	*4.4%*	*-1.8%*	*-2.5%*	*-8.4%*	*-2.3%*	*-4.8%*
Other Customers	$182	$175	$184	$206	$747	$218	$224	$239	$239	$920	$243
% growth	*25.5%*	*19.0%*	*24.3%*	*27.2%*	*24.1%*	*19.8%*	*28.0%*	*29.9%*	*16.0%*	*23.2%*	*11.5%*
Revenue	**$342**	**$340**	**$347**	**$384**	**$1,413**	**$385**	**$386**	**$398**	**$402**	**$1,571**	**$402**
% growth	*20.0%*	*19.3%*	*17.2%*	*17.4%*	*18.4%*	*12.6%*	*13.5%*	*14.7%*	*4.7%*	*11.2%*	*4.4%*
Adjusted EBITDA	**$82**	**$60**	**$62**	**$61**	**$265**	**$63**	**$63**	**$79**	**$72**	**$277**	**$65**
% growth	*70.8%*	*36.4%*	*31.9%*	*-4.7%*	*30.5%*	*-23.2%*	*5.0%*	*27.4%*	*18.0%*	*4.5%*	*3.2%*
Adjusted EBITDA Margin	**24.0%**	**17.6%**	**17.9%**	**15.9%**	**18.8%**	**16.4%**	**16.3%**	**19.8%**	**17.9%**	**17.6%**	**16.2%**

(1) Conifer's Adjusted EBITDA in Q1'15 benefitted from approximately $10 million of non-recurring customer incentive revenue.

Note: Tenet and Catholic Health Initiatives represented approximately 75% of Conifer's revenue in Q1'17.

Tenet Outlook for 2017

Adjusted EBITDA Outlook range raised by $25 million to reflect a change in pension accounting rules

$ in millions, except EPS	2017 Outlook
Net Revenue	$19,700 - $20,100
Adjusted EBITDA (1)	$2,525 - $2,625
Adjusted EBITDA Margin (1)	12.8% - 13.1%
Adjusted diluted E.P.S. from continuing operations (1)	$1.05 - $1.30
Adjusted Cash Flow from Operations (1)	$1,300 - $1,550
Capital Expenditures	$700 - $750
Adjusted Free Cash Flow (1)	$600 - $800
Assumptions:	
Bad Debt Ratio	6.75% - 7.25%
Total Hospital Expenses per Adjusted Admission Growth	2.5% - 3.5%
Equity in Earnings of Unconsolidated Affiliates	$145 - $155
Electronic Health Record Incentives	$8 - $10
Depreciation and Amortization	$860 - $880
Interest Expense	$1,025 - $1,035
Effective Tax Rate (2)	19% - 21%
Net Income Attributable to Noncontrolling Interests (3)	$390 - $410
Fully diluted weighted average shares outstanding	102

Note: The Outlook for 2017: a) includes a full year of financial results from hospitals which may be divested in 2017; b) assumes that the new California Provider Fee program is approved by December 31, 2017; and c) excludes approximately $40 million of negative Adjusted EBITDA that the Company expects to incur in its health plan business prior to the sale or exit of this business in 2017.

(1) Excludes restructuring charges, acquisition-related costs, litigation costs and settlements, discontinued operations, and gains on sales, consolidation and deconsolidation of facilities.

(2) In order to estimate Tenet's income tax expense in 2017, the following formula should be used: a) start with pre-tax income, which is estimated to be $615-$685 million; b) subtract GAAP NCI expense, which is estimated to be $390-$410 million in 2017; c) add back permanent differences and non-deductible items, which are estimated to be approximately $25-$35 million in 2017; d) add back approximately $45 million of non-cash NCI expense that Tenet is recognizing related to the portion of USPI that the company does not own; and, e) multiply the result by a 40% tax rate. The result is an effective tax rate of approximately 19%-21% on Tenet's pre-tax income.

(3) This represents GAAP NCI expense to be recorded on the income statement, including approximately $45 million related to portion of USPI that Tenet does not own and approximately $50-$55 million related to the portion of Conifer that Tenet does not own. Cash distributions paid to noncontrolling interests are expected to be $280-$320 million.

Segment Outlook for 2017

Hospital segment Adjusted EBITDA Outlook raised by $25 million to reflect a change in pension accounting rules

Hospital Operations and Other Segment

Adjusted EBITDA	**$1.550 - $1.620 billion**
Noncontrolling Interest (1)	$40 - $45 million
Net Patient Revenue Growth (2)	2% - 4%
Pro forma Adjusted EBITDA Growth (3)	1% - 6%
Adjusted Admissions Growth (2)	(1.0%) - 1.0%
Net Revenue per Adjusted Admission (2)	2.5% - 3.5%
Admissions Growth (2)	(1.0%) - 1.0%

(1) Based on GAAP NCI expense.

(2) Growth rates on a same hospital basis.

(3) Excluding: a) Electronic health record incentives in both 2016 and 2017, b) $25 million of EBITDA in Q1'16 generated by hospitals that have been divested, and c) $37 million of health plan losses in 2016.

Ambulatory Segment

Adjusted EBITDA	**$695 - $715 million**
Noncontrolling Interest (1)	$300 - $310 million
Net Revenue Growth (2)	4% - 6%
Adjusted EBITDA Growth	13% - 16%
Adjusted EBITDA less NCI Growth (3)	11% - 14%
Case Growth (2)	2.0% - 3.0%
Net Revenue per Case Growth (2)	2.0% - 3.0%

(1) Based on GAAP NCI expense, including approximately $45 million related to portion of USPI that Tenet does not own.

(2) Growth rates on a same facility system wide basis.

(3) Represents the expected growth in EBITDA less facility-level NCI. Calculated using $395 million of Ambulatory segment EBITDA less facility level NCI in 2016. This calculation excludes $65 million of NCI in 2016 and an estimated $45 million in 2017 related to the portion of USPI that Tenet does not own.

Conifer Segment

Adjusted EBITDA	**$280 - $290 million**
Noncontrolling Interest (1)	$50 - $55 million
Net Revenue Growth	3% - 5%
Adjusted EBITDA Growth	1% - 5%

(1) Based on GAAP NCI expense. Cash NCI distributions will be zero.

Summary

- ✓ *Adjusted EBITDA was $527 million – at the high end of the Outlook range.*
- ✓ *Hospital segment same-hospital patient revenue declined 1.0%*
  - *Adjusted admissions declined 2.5% and were down 0.8% excluding patients insured by Humana*
  - *Revenue per adjusted admission increased 3.0% adjusting for the California Provider Fee revenue*
- ✓ *Ambulatory Care segment delivered strong same-facility system-wide revenue growth of 6.1% in the quarter, with cases increasing 0.5%, and Adjusted EBITDA less facility-level NCI growth of 11.1%*
- ✓ *Conifer grew revenue by 4.4% and Adjusted EBITDA by 3.2%, delivering a margin of 16.2%*
- ✓ *Adjusted Free Cash Flow was $9 million in Q1'17 and is expected to be $600-$800 million in 2017*
- ✓ *Reached new multi-year agreement with Humana*
- ✓ *Announced the sale of the Company's hospitals in Houston and an acceleration of the buy-up of USPI*
- ✓ *Adjusted EBITDA expected to be $2.525 billion to $2.625 billion in 2017 or growth of 2% to 6%* (1)

(1) Adjusted EBITDA growth of 2% to 6% in 2017 is based on restated 2016 Adjusted EBITDA of $2.478 billion which is comprised of: (i) $2.413 billion of Adjusted EBITDA reported in 2016, plus (ii) $28 million due to a change in pension accounting which would have lowered Salaries, Wages and Benefits expense by a corresponding amount in 2016, plus (iii) $37 million in health plan losses in 2016 which are now excluded from the Company's definition of Adjusted EBITDA.

Appendix and Reconciliation of Non-GAAP Financial Measures

Non-GAAP Financial Measures

Adjusted EBITDA, a non-GAAP measure, is defined by the Company as net income (loss) attributable to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss (income) attributable to noncontrolling interests, (3) income (loss) from discontinued operations, (4) income tax benefit (expense), (5) other non-operating income (expense), net, (6) gain (loss) from early extinguishment of debt, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested operations and closed businesses (i.e., the Company's health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

Adjusted net income (loss) from continuing operations attributable to Tenet Healthcare Corporation common shareholders, a non-GAAP measure, is defined by the Company as net income (loss) attributable to Tenet Healthcare Corporation common shareholders before (1) impairment and restructuring charges, and acquisition-related costs, (2) litigation and investigation costs, (3) gains on sales, consolidation and deconsolidation of facilities, (4) income (loss) from divested operations and closed businesses (5) the associated impact of these four items on taxes and noncontrolling interests, and (6) net income (loss) from discontinued operations. Adjusted diluted earnings (loss) per share from continuing operations, a non-GAAP term, is defined by the Company as Adjusted net income (loss) from continuing operations attributable to Tenet Healthcare Corporation common shareholders divided by the weighted average primary or diluted shares outstanding in the reporting period.

Free Cash Flow, a non-GAAP measure, is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment from continuing operations.

Adjusted Free Cash Flow, a non-GAAP measure, is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities from continuing operations, less (2) purchases of property and equipment from continuing operations. Adjusted net cash provided by (used in) operating activities, a non-GAAP measure, is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and, (2) net cash provided by (used in) operating activities from discontinued operations.

The Company believes the foregoing non-GAAP measures are useful to investors and analysts because they present additional information on the Company's financial performance. Investors, analysts, Company management and the Company's Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the company's financial and operating performance and compare the Company's performance to its peer companies, which utilize similar non-GAAP measures in their presentations. The Human Resources Committee of the Company's Board of Directors also uses certain of these measures to evaluate management's performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

(continued on the following page)

Non-GAAP Financial Measures

(continued from the prior page)

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company's common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

We use, and we believe investors and analysts use, Free Cash Flow and Adjusted Free Cash Flow as supplemental measures to analyze cash flows generated from our operations because we believe it is useful to investors in evaluating our ability to fund distributions paid to noncontrolling interests, acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in our financial statements, they do not provide a complete measure of our operating performance. For example, the Company's definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company's Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, (ii) distributions paid to noncontrolling interests, or (iii) payments under the Put/Call Agreement for USPI redeemable noncontrolling interest, which are recorded on the Statement of Cash Flows as the purchase of noncontrolling interest. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company's financial performance.

A reconciliation of Adjusted EBITDA to net income (loss) attributable to Tenet Healthcare Corporation common shareholders, the most comparable GAAP measure, is set forth in Table #1 below for the three months ended March 31, 2017 and 2016. A reconciliation of Adjusted net income from continuing operations attributable to Tenet Healthcare Corporation common shareholders to net income (loss) attributable to Tenet Healthcare Corporation common shareholders, the most comparable GAAP measure, is set forth in Table #2 below for the three months ended March 31, 2017 and 2016. A reconciliation of Free Cash Flow and Adjusted Free Cash Flow to net cash provided by (used in) operating activities, the most comparable GAAP measure, is set forth in Table #3 below for the three months ended March 31, 2017 and 2016.

Table #1 – Reconciliation of Adjusted EBITDA to Loss Attributable to Tenet Healthcare Corporation Common Shareholders

(Unaudited)

(Dollars in millions)	Three Months Ended March 31, 2017	Three Months Ended March 31, 2016
	(Expense) Income	
Net loss attributable to Tenet Healthcare Corporation common shareholders	**$ (53)**	**$ (59)**
Less: Net income attributable to noncontrolling interests	(89)	(93)
Net loss from discontinued operations, net of tax	(1)	(4)
Net income from continuing operations	37	38
Income tax benefit (expense)	33	(67)
Other non-operating income (expense), net	(5)	(6)
Interest expense	(258)	(243)
Operating income	267	354
Litigation and investigation costs	(5)	(173)
Gains on sales, consolidation and deconsolidation of facilities	15	147
Impairment and restructuring charges, and acquisition-related costs	(33)	(28)
Depreciation and amortization	(221)	(212)
Income (loss) from divested and closed businesses	(16)	3
Adjusted EBITDA	**$ 527**	**$ 617**
Net operating revenues	$ 4,813	$ 5,044
Less Net operating revenues from health plans	65	127
Adjusted net operating revenues	**$ 4,748**	**$ 4,917**
Net loss from continuing operations as a % of net operating revenues	**(1.1)%**	**(1.1)%**
Adjusted EBITDA as % of adjusted net operating revenues (Adjusted EBITDA margin)	**11.1 %**	**12.5 %**

Table #2 – Pre-Tax, After-Tax and Earnings Per Share Impact of Certain Items on Continuing Operations

(Unaudited)

(Dollars in millions except per share amounts)	Three Months Ended March 31, 2017	Three Months Ended March 31, 2016
Adjustments to calculate Adjusted Diluted EPS	(Expense) Income	
Impairment and restructuring charges, and acquisition-related costs	$ (33)	$ (28)
Litigation and investigation costs	(5)	(173)
Gain on sales, consolidation and deconsolidation of facilities	15	147
Income (loss) from divested and closed businesses	(16)	3
Pre-tax impact	$ (39)	$ (51)
Tax impact of above items	$ 14	$ (31)
Total after-tax impact	$ (25)	$ (82)
Noncontrolling interests impact	—	(18)
Total loss from items above	**$ (25)**	**$ (100)**
Net loss attributable to common shareholders	**$ (53)**	**$ (59)**
Less net loss discontinued operations, net of tax	(1)	(4)
Net loss from continuing operations, net of tax	**$ (52)**	**$ (55)**
Net loss from adjustments above	25	100
Adjusted net income (loss) from continuing operations attributable to common shareholders	**$ (27)**	**$ 45**
Weighted average dilutive shares outstanding (in thousands)	**100,000**	**100,335**
Diluted loss per share from continuing operations	**$ (0.52)**	**$ (0.56)**
Adjusted diluted EPS from continuing operations	**$ (0.27)**	**$ 0.45**

Table #3 – Reconciliations of Free Cash Flow and Adjusted Free Cash Flow

(Unaudited)

(Dollars in millions)	Three Months Ended March 31, 2017	Three Months Ended March 31, 2016
Net cash provided by (used in) operating activities	**$ 186**	**$ 147**
Purchases of property and equipment	(198)	(208)
Free cash flow	**$ (12)**	**$ (61)**
Net cash provided by (used in) investing activities	**$ (189)**	**$ 320**
Net cash provided by (used in) financing activities	**$ (141)**	**$ (95)**
Net cash provided by (used in) operating activities	**$ 186**	**$ 147**
Less:		
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(24)	(69)
Net cash used in operating activities from discontinued operations	3	(3)
Adjusted net cash provided by operating activities – continuing operations	**207**	**219**
Purchases of property and equipment – continuing operations	(198)	(208)
Adjusted free cash flow – continuing operations	**$ 9**	**$ 11**

Table #4 – Reconciliation of Outlook Adjusted EBITDA to Outlook Net Income Attributable to Tenet Healthcare Corporation Common Shareholders

(Unaudited)

(Dollars in millions)	Q2 2017 Low	Q2 2017 High	2017 Low	2017 High
Net income (loss) attributable to Tenet Healthcare Corporation common shareholders	**$ (35)**	**$ (25)**	**$ 61**	**$ 95**
Less: Net income attributable to noncontrolling interests	(90)	(100)	(390)	(410)
Net loss from discontinued operations, net of tax	(5)	-	(10)	-
Income from continuing operations	60	75	461	505
Income tax benefit (expense)	(10)	(20)	(91)	(107)
Income from continuing operations, before income taxes	70	95	552	612
Interest expense	(250)	(260)	(1,025)	(1,035)
Other non-operating income (expense), net	(5)	(5)	(25)	(25)
Operating income	325	360	1,602	1,672
Gains on sales, consolidation and deconsolidation of facilities[(a)]	-	-	15	15
Impairment and restructuring charges, acquisition-related costs and litigation costs and settlements[(a)]	-	-	(38)	(38)
Depreciation and amortization	(215)	(225)	(860)	(880)
Income (loss) from divested and closed businesses	(10)	(15)	(40)	(50)
Adjusted EBITDA	**$ 550**	**$ 600**	**$ 2,525**	**$ 2,625**
Adjusted EBITDA as % of net operating revenues (Adjusted EBITDA margin)	**11.3 %**	**11.9 %**	**12.8 %**	**13.1 %**
Net income (loss) from continuing operations	**$ (30)**	**$ (25)**	**$ 71**	**$ 95**
Net income (loss) from continuing operations as a % of operating revenues	**(0.6)%**	**(0.5)%**	**0.4 %**	**0.5 %**
Net operating revenues	**$ 4,850**	**$ 5,050**	**$ 19,700**	**$ 20,100**
Adjusted EBITDA	**$ 550**	**$ 600**	**$ 2,525**	**$ 2,625**
Depreciation and amortization	(215)	(225)	(860)	(880)
Interest expense	(250)	- (260)	(1,025)	(1,035)
Other non-operating income (expense), net	(5)	(5)	(25)	(25)
Adjusted income from continuing operations before income taxes	80	110	615	685
Income tax benefit (expense)	(10)	(20)	(118)	(142)
Adjusted net income from continuing operations	70	90	497	543
Net income attributable to noncontrolling interests	(90)	(100)	(390)	(410)
Adjusted net income (loss) from continuing operations attributable to common shareholders	**$ (20)**	**$ (10)**	**$ 107**	**$ 133**
Basic weighted average shares outstanding (in millions)	**100**	**100**	**100**	**100**
Fully diluted weighted average shares outstanding (in millions)	**102**	**102**	**102**	**102**
Diluted earnings (loss) per share from continuing operations	**$ (0.30)**	**$ (0.25)**	**$ 0.70**	**$ 0.93**
Adjusted diluted earnings (loss) per share from continuing operations	**$ (0.20)**	**$ (0.10)**	**$ 1.05**	**$ 1.30**

[(a)] The Company does not forecast impairment and restructuring charges, acquisition-related costs and litigation costs and settlements and gains on sales, consolidation and deconsolidation of facilities because the Company does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

Table #5 – Reconciliation of Outlook Adjusted Free Cash Flow for the Year Ending December 31, 2017

(Dollars in millions)	2017	
	Low	High
Net cash provided by operating activities	**$ 1,271**	**$ 1,526**
Less:		
Payments for restructuring charges, acquisition-related costs and litigation costs and settlements (1)	(24)	(24)
Net cash used in operating activities from discontinued operations	(5)	0
Adjusted net cash provided by operating activities – continuing operations	**$ 1,300**	**$ 1,550**
Purchases of property and equipment – continuing operations	(700)	(750)
Adjusted free cash flow – continuing operations (2)	**$ 600**	**$ 800**

(1) The Company does not forecast impairment and restructuring charges, acquisition-related costs and litigation costs and settlements because the Company does not believe that it can forecast these items with sufficient accuracy since some of these items may be indeterminable at the time the Company provides its financial Outlook.

(2) The Company's definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company's Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, (ii) distributions paid to noncontrolling interests, or (iii) payments under the Put/Call Agreement for USPI redeemable noncontrolling interest, which are recorded on the Statement of Cash Flows as the purchase of noncontrolling interest.

tenet HEALTH